Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ziprasidone and weight gain.

Sol Jaworowski1, Shoshana Hauser, Joseph Mergui

  • 1Shaare Zedek Medical Centre, Jerusalem, Israel. evesol@netvision.net.il

Clinical Neuropharmacology
|July 15, 2004
PubMed
Summary

Ziprasidone, an antipsychotic medication, can cause significant weight gain in adolescents. Clinicians should monitor for this adverse effect, even though it is marketed as weight-neutral.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical clowns versus sedation for paediatric urinary catheter insertion-A randomised pilot study.

Acta paediatrica (Oslo, Norway : 1992)·2023
Same author

Telepsychiatry for Patients with Post-traumatic Stress Disorder During the COVID-19 Outbreak.

Current treatment options in psychiatry·2021
Same author

Factitious disorder of a 17-year-old female during COVID-19 pandemic.

Journal of paediatrics and child health·2021
Same author

Three Cases of COVID-19-related First Onset Brief Reactive Psychosis.

The Israel Medical Association journal : IMAJ·2020
Same author

A contextual approach to routinely elicit a trauma-oriented history.

The British journal of psychiatry : the journal of mental science·2020
Same author

Simulation training in addiction psychiatry.

Evidence-based mental health·2020

Area of Science:

  • Pharmacology
  • Adolescent Medicine
  • Psychiatry

Background:

  • Ziprasidone is an atypical antipsychotic medication.
  • It is often prescribed for conditions such as schizophrenia and bipolar disorder.
  • The drug is marketed as having a lower risk of significant weight gain compared to other antipsychotics.

Observation:

  • A case study involving a 12-year-old male is presented.
  • The patient experienced substantial weight gain.
  • This weight gain occurred within a three-month period after initiating Ziprasidone treatment.

Findings:

  • The case demonstrates that Ziprasidone can be associated with significant weight gain.
  • This finding contrasts with the drug's marketing profile.
  • Adolescents may be particularly susceptible to this side effect.

Implications:

  • Clinicians must be aware of the potential for Ziprasidone-induced weight gain in pediatric patients.
  • Monitoring weight is crucial for patients treated with Ziprasidone.
  • Further research may be needed to understand the mechanisms and prevalence of this adverse effect in adolescents.

Related Experiment Videos